Caplin Point Laboratories Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ov59w2jr9gvvixd1qblzlepa.pdf

Key Takeaways


Caplin Steriles: The Growth Engine

Vivek Partheeban: “We do not want to go to the very large GPOs and distributors and then try and sell our product because that is a space that sort of crowded with big boys, right including the Lupins of the world. What we want to do is there is a certain amount of markets... anywhere between 20% to 30% that is outside of these large GPOs and IDMs... we can actually sell our product even if it is smaller volumes we can actually sell it to for higher margins.”

Capex & Capacity Expansion


Margin Quality & Sustainability

C.C. Paarthipan: “What is important, what cannot be cured must be endured and endurance is the key. When we have the great, definitely whatever delay which happens actually eventually it will be complete... we have not been borrowing money from any bank it is all happening from our own internal accrual.”

Working Capital & Balance Sheet


New Geographies & Business Development


Product Pipeline & R&D


Guidance & Commitments

CommitmentSpecificsTimeline
Gross margin normalizationSustainable level is 55-56% (vs 57.4% in Q2)Long-run
PAT margin normalizationSustainable level is 24-25%Long-run
All six capex projects completed₹600-650 Crores plan fully executedQ3 FY2025
Oncology tablet/capsule commercial productionStart of commercial batchesWithin 6 months
API facility in Vizag completedFacility ready6-9 months
Caplin Steriles US own-label revenueFirst revenue from US front-end6-9 months
Prefilled syringe line qualifiedQualifications completeBefore end of FY2024
Caplin Steriles revenue target$100 millionFY2027
Mexico meaningful revenueOwn front-end generating material sales~18 months and beyond
Ophthalmic product approvals2-3 additional approvals3-5 months
Revenue aspiration₹2,000 Crores salesFY2024-25
Revenue aspiration₹4,000-5,000 Crores sales5 years out

Key Metrics

MetricQ2 FY24
Revenue (H1 FY24)₹838 cr, close to FY2020 full-year revenue of ₹863 cr
PAT (H1 FY24)₹219 cr, surpassed FY2020 full-year PAT of ₹215 cr
Gross margin57.4%, up from 54.3% YoY; driven by niche products, oncology, and soft gels
EBITDA margin35.4%, up from 32.4% YoY
EBIT margin32.6%, up from 29.3% YoY
PAT margin26.3%, up from 24.2% YoY
Cash and cash equivalents₹825 cr, held in fixed deposits
Receivable days103 days, up from 97 days; ₹110 cr collected in Oct and Q3 to date
Caplin Steriles revenue₹75 cr in Q2, up from ₹46 cr in Q1
Caplin Steriles EBITDA₹10 cr in Q2, up from ₹2.5 cr in Q1; after expensing all R&D and ANDA fees
LATAM revenue₹335 cr in Q2, marginal dip from ~₹350 cr in Q1 due to temporary Guatemala disruption
ANDAs under review with FDA13, of which 11 in Caplin Steriles name; includes 6 ophthalmic, 4 premixed bags, 3 injectables
Capex spent (last 3 years)₹459 cr; additional ₹370 cr identified for next 12-18 months, of which ₹200-250 cr crystallized
Products registered in Central America & Caribbean550 to 560 across six to seven countries
Saudi pipeline potential$80 million